Helene joined UCB (then Celltech) in 1989 after 2 years at the MRC Laboratory of Molecular Biology Cambridge, and has gained expertise in a range of antibody technologies. Her PhD studies at UCB in gene therapy generated the first co-stimulation signal inclusive (now termed “second generation”) CAR-T cell constructs. She has led a variety of antibody technology teams & early stage therapeutic antibody discovery projects for oncology, bone, immunology/inflammation & CNS targets. Helene now leads the UCB Functional Screening project team; combining cutting edge antibody & screening technology to discover break-through bispecific antibody drugs across multiple therapeutic areas.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
UCB | Head of Bispecific Target Discovery | Jan 1, 2019 | — | Detail |
UCB | Director, Functional Screening | Aug 1, 1989 | — | Detail |